Plasma levels of EPAC1 were significantly lower in patients with SIS > 4 compared to controls (SIS = 0) or moderate CAD (SIS 1–4) group, both in women (7.76 ± 3.27 vs 11.18 ± 3.20 ng/mL or 11.15 ± 2.82 ng/mL, p = 0.004 or p = 0.009, respectively) and men (7.80 ± 3.42 vs 14.10 ± 2.68 ng/mL or 12.32 ± 4.01 ng/mL, p < 0.001 for both comparisons) (Fig. 2A). Here, RAPGEF3 is linked to coronary artery disorder.